BridgeBio Oncology Therapeutics, Inc.
BBOT
$6.76
-$2.11-23.76%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 296.96% | 257.12% | 217.43% | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 109.93% | 90.69% | 80.33% | -- | -- |
| Operating Income | -109.93% | -90.69% | -80.33% | -- | -- |
| Income Before Tax | -108.13% | -90.50% | -80.47% | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -108.13% | -90.50% | -80.47% | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -108.13% | -90.50% | -80.47% | -- | -- |
| EBIT | -109.93% | -90.69% | -80.33% | -- | -- |
| EBITDA | -110.11% | -90.81% | -80.45% | -- | -- |
| EPS Basic | 78.28% | 80.15% | 78.79% | -- | -- |
| Normalized Basic EPS | 78.28% | 80.15% | 78.79% | -- | -- |
| EPS Diluted | 78.28% | 80.15% | 78.79% | -- | -- |
| Normalized Diluted EPS | 78.28% | 80.15% | 78.79% | -- | -- |
| Average Basic Shares Outstanding | 41,765.23% | 36,198.27% | 44,353.16% | -- | -- |
| Average Diluted Shares Outstanding | 41,765.23% | 36,198.27% | 44,353.16% | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |